Balstilimab plus zalifrelimab data published in journal of clinical oncology (jco)

Lexington, mass., dec. 22, 2021 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the publication of results in the journal of clinical oncology (jco) from a global phase 2 clinical study of balstilimab (bal) plus zalifrelimab (zal) in second-line (2l) recurrent/metastatic cervical cancer patients who had relapsed after treatment with platinum-based therapy.
AGEN Ratings Summary
AGEN Quant Ranking